CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Revolution Medicines, Inc. (RVMD) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Revolution Medicines, Inc. (RVMD)

Biological Products, (No Diagnostic Substances) · market cap $41.1B · as of 2026-11-20

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2027-05-31 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Revolution Medicines (RVMD) is a clinical-stage oncology company valued at about $34.2B (≈214.3M shares at ~$159.43). Its lead asset, daraxonrasib, is in Phase 3 for non-small cell lung cancer, alongside Phase 3 programs listed for RMC-6236 in colorectal cancer and zoldonrasib in pancreatic cancer. The company reported no revenue in 2024 or 2025, a 2025 net loss of $1.13B, and $815.4M of cash in our data. Our calendar's only dated upcoming catalysts are two estimated mid-2027 Phase 2 RMC-6236 colorectal readouts.
The catalyst path
  • 2027-05-31 (est.)Phase 2 · RMC-6236imp 7/10
  • 2027-06-15 (est.)Phase 2 · RMC-6236imp 7/10
Pipeline
AssetPhaseIndication
daraxonrasibPhase 3NSCLC (Non-small Cell Lung Cancer)
RMC-4630Phase 2Non-Small Cell Lung Cancer
RMC-6236Phase 3Colorectal Cancer
RMC-6291Phase 2Non-Small Cell Lung Cancer, NSCLC
CobimetinibPhase 2Solid Tumor
zoldonrasibPhase 3Pancreatic Cancer
pemetrexed + cisplatin/carboplatinPhase 3NSCLC
Liposomal irinotecanPhase 3Pancreatic Cancer
mFOLFOX6 regimenPhase 2Colorectal Cancer
Leucovorin (Calcium Folinate)Phase 3Pancreatic Cancer
IvonescimabPhase 2Advanced Solid Tumors
ElironrasibPhase 2Advanced Solid Tumors
cetuximab (Cohort C2 Only)Phase 2Advanced Solid Tumors
Daraxonrasib (Cohort B1 only)Phase 2Advanced Solid Tumors
TNG462Phase 2PDAC
Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only)Phase 2Advanced Solid Tumors
Gemcitabine (GEM)Phase 3Pancreatic Cancer
mFOLFIRINOX regimenPhase 2Colorectal Cancer
RMC-9805Phase 2Colorectal Cancer
Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only)Phase 2Advanced Solid Tumors
Price & technical context
3-month
-23.9%
6-month
+3.7%
12-month
+125.9%
52-wk range
$69.88–$221.15
vs 50-day MA
-16.5%
vs 200-day MA
-1.1%
Realized vol
63.7%
Max drawdown
-48.6%

Daily closes through 2026-11-19. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for RVMD (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.